logo
Brits' 30 most common ‘everyday habits' including writing to-do lists, morning walks and scrolling social media

Brits' 30 most common ‘everyday habits' including writing to-do lists, morning walks and scrolling social media

The Sun23-05-2025
Brits are embracing little tweaks to elevate their daily routines to help them break free from "autopilot".
A poll of 5,000 adults found 45 per cent are making small changes to their everyday habits, such as putting music on, stretching, and taking time to properly savour a coffee break.
3
3
3
Other adjustments include adding a morning walk to the start of the day, or taking time to "review" daily targets.
The shift towards more mindful living comes after 35 per cent admitted they are tired of the same mundane schedule day in, day out.
With taking vitamins, watering the plants, and stretching also making the list of new ways they are living life more fully.
The research was commissioned by Costa Coffee, which teamed up with psychologist Jo Hemmings to explore the power of having rituals.
She said: 'Incorporating mindful rituals into your day can reset the mind, reduce stress, and improve overall wellbeing.
'Routines give us structure and stability, which are essential for our mental wellbeing — but doing the same thing every day without variation can make life feel monotonous.
'Tiny tweaks can help inject energy and intention into the everyday.
'It keeps the brain engaged rather than switching to autopilot.'
Most of the nation's key daily rituals take place in the morning (44 per cent) compared to only nine per cent who indulge in the evening.
And as many as 60 per cent admitted they feel 'out of sync' if they don't stick to their usual routines.
While 74 per cent believe these small daily habits can have a long-term impact on someone's wellbeing.
And 45 per cent reckon even the smallest disruption to their usual routine can throw off their entire day.
According to the OnePoll.com figures, 73 per cent of coffee drinkers who have daily rituals consider it an essential part of their daily schedule.
And 38 per cent even believe they're more able to have deeper and more meaningful conversations over a cup of coffee.
While 33 per cent usually pair theirs with breakfast, 23 per cent take the time to use it as a moment for mindfulness or relaxation.
It was also found 49 per cent enjoy a quiet moment to themselves with their coffee, while 32 per cent catch up with friends over one and 30 per cent read a book or newspaper while drinking it.
Gennaro Pelliccia, master of coffee at Costa Coffee, said: 'These findings show just how powerful everyday rituals can be — especially when it comes to coffee.
'For many, that daily cup isn't just a habit, it's a grounding moment of calm, connection, and reflection.
'Whether it's a quiet pause before the day begins or a conversation shared with a friend, we're proud to be part of the small moments that bring people closer to themselves and those around them.'
TOP 30 WAYS BRITS ELEVATE THEIR ROUTINES
The top 30 ways for Brits to elevate their routines and boost their days have been revealed.
The list has a wide variety of activities, with some people preferring to take it easy while others want to kick-start their day with a to-do list.
Ranked from most popular to least popular, the list includes:
Listen to music
Tidy the house
Take vitamins
Get up to date on the news
Savour a coffee break
Scroll through social media
Spend time with pets
Sit in the sun
Open all the windows to let fresh air in
Morning walks
Read a chapter of a book
Drink a pint of water
Do a skincare routine
Water the plants
Afternoon walks
Evening walks
Write a daily to-do list
Listen to a podcast
Catch up on the previous night's messages from friends/family
Do stretches
Meet a friend for a coffee
Send a message to family/friends wishing them a good day
Call/text your mum
Review goals for the day
Meditate
Light a candle or use essential oils
Intentional screen breaks
Daily affirmations
Morning mindfulness
Practice yoga
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pharmacy warning of unsustainable demand for weight loss medication
Pharmacy warning of unsustainable demand for weight loss medication

The Independent

time21 minutes ago

  • The Independent

Pharmacy warning of unsustainable demand for weight loss medication

The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'

Roche to investigate whether new drug can delay or prevent Alzheimer's disease
Roche to investigate whether new drug can delay or prevent Alzheimer's disease

Reuters

timean hour ago

  • Reuters

Roche to investigate whether new drug can delay or prevent Alzheimer's disease

July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.

Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports

Reuters

time2 hours ago

  • Reuters

Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports

July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store